On Wednesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss.

The company reported an adjusted net loss of $68 million versus a net income of $17 million.

Ionis reported quarterly sales of $227 million, down from $325 million a year ago, beating the consensus of $137.6 million.

Ionis says 2024 revenue of $705 million exceeded guidance as the company continued to generate revenue from diverse sources. The company added new revenue sources in 2024 with the launch of Wainua and Tryngolza in the U.S. in late January and late December, respectively.

Ionis ended 2024 with a cash position of $2.3 billion in cash, cash equivalents, and short-term investments, exceeding its revised guidance.

Also Read: FDA Approves Ionis Pharmaceuticals’ Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

CEO Brett Monia commented, “With the recent launch of our first independent medicine, Tryngolza for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company.”

“Over the next three years, we expect three more independent launches, including donidalorsen later this year for hereditary angioedema and olezarsen for severe hypertriglyceridemia in 2026, pending Phase 3 results in the second half of this year,” Monia added.

Guidance: Ionis Pharmaceuticals forecasts 2025 revenue of over $600 million compared to the consensus of $675.95 million.

The company expects a 2025 adjusted operating loss of less than $495 million, with cash, cash equivalents, and short-term investments of ~$1.7 billion.

Price Action: IONS stock is up 0.62% at $32.15 at the last check on Wednesday.

Read Next:

• Garmin Q4 Earnings: Wearables and Adventure Watches Drive Growth, 20% Dividend Hike, Stock Soars